The multirole of liposomes in therapy and prevention of infectious diseases

R Nisini, N Poerio, S Mariotti, F De Santis… - Frontiers in …, 2018 - frontiersin.org
Liposomes are closed bilayer structures spontaneously formed by hydrated phospholipids
that are widely used as efficient delivery systems for drugs or antigens, due to their capability …

Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases

G Volpedo, L Costa, N Ryan, G Halsey… - Journal of Venomous …, 2019 - SciELO Brasil
Abstract Neglected Tropical Diseases (NTDs) comprise of a group of seventeen infectious
conditions endemic in many developing countries. Among these diseases are three of …

Subcutaneous drug delivery from nanoscale systems

L Tomasini, M Ferrere, J Nicolas - Nature Reviews Bioengineering, 2024 - nature.com
Various types of nanoscale drug delivery systems (DDSs) have been developed for
therapeutic and/or diagnostic applications. However, most systems have been designed for …

Targeting channels and transporters in protozoan parasite infections

A Meier, H Erler, E Beitz - Frontiers in chemistry, 2018 - frontiersin.org
Infectious diseases caused by pathogenic protozoa are among the most significant causes
of death in humans. Therapeutic options are scarce and massively challenged by the …

[HTML][HTML] Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum

LM Monteiro, R Löbenberg, EJ Barbosa… - European Journal of …, 2022 - Elsevier
Leishmaniasis, a neglected tropical disease, is prevalent in 98 countries with the occurrence
of 1.3 million new cases annually. The conventional therapy for visceral leishmaniasis …

Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates

S Jain, U Sahu, A Kumar, P Khare - Pharmaceutics, 2022 - mdpi.com
Leishmaniasis is a tropical disease caused by a protozoan parasite Leishmania that is
transmitted via infected female sandflies. At present, leishmaniasis treatment mainly counts …

Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential

JM Ribeiro, ML Rodrigues-Alves, E Oliveira… - International …, 2022 - Elsevier
Visceral leishmaniasis (VL) is an infectious disease caused by Leishmania infantum (L.
infantum). Currently, there are no vaccines and/or prophylactic therapies against VL, and the …

In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis

LP Borba-Santos, TL Barreto, T Vila… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Sporotrichosis has become an important zoonosis in Brazil, and Sporothrix brasiliensis is
the primary species transmitted by cats. Improvement of animal treatment will help control …

Nano-and microformulations to advance therapies for visceral leishmaniasis

DM Varma, EA Redding, EM Bachelder… - … biomaterials science & …, 2020 - ACS Publications
Visceral leishmaniasis (VL) is a deadly, vector-borne, neglected tropical disease endemic to
arid parts of the world and is caused by a protozoan parasite of the genus Leishmania …

3, 5-Dimethyl-4-isoxazoyl selenocyanate as promising agent for the treatment of Leishmania infantum-infected mice

V Alcolea, E Moreno, M Etxebeste-Mitxeltorena… - Acta Tropica, 2021 - Elsevier
Compounds 1 and 2 (selenocyanate and diselenide derivatives, respectively) were
evaluated for their potential use in vivo against visceral leishmaniasis (VL). Both entities …